MEDPACTO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,510 KRW | -2.86% |
|
+3.26% | +31.35% |
| 2023 | MedPacto, Inc. announced that it has received KRW 10.85806127 billion in funding from Theragen Etex Co.,Ltd. | CI |
| 2023 | South Korean Shares Nearly Unchanged Ahead of US Inflation Data | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 243B 334,651B 332B |
|---|---|---|---|---|---|
| Net income 2022 | -35.75B -49,213B -48.87B | Net income 2023 | -35.32B -48,623B -48.29B | EV / Sales 2022 | - |
| Net cash position 2022 | 33.58B 46,218B 45.9B | Net cash position 2023 | 70.18B 96,595B 95.92B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-13
x | P/E ratio 2023 |
-4.35
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.86% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.86% | ||
| 1 week | +3.26% | ||
| Current month | -27.40% | ||
| 1 month | -40.86% | ||
| 3 months | +14.99% | ||
| 6 months | +28.17% | ||
| Current year | +31.35% |
1 week
9 150.00
10 920.00
1 month
8 590.0014 230.00
Current year
6 260.0017 240.00
1 year
6 110.0023 900.00
3 years
6 110.0085 000.00
5 years
6 110.00134 200.00
10 years
6 110.00134 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Seong-Jin Kim
FOU | Founder | 70 | - |
Seon-Jeong Kim
DFI | Director of Finance/CFO | 56 | - |
Gi-Baek Ham
CTO | Chief Tech/Sci/R&D Officer | 65 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seong-Jin Kim
FOU | Founder | 70 | - |
Jeong-Im Heo
BRD | Director/Board Member | 53 | - |
Young-Shik Kim
BRD | Director/Board Member | 62 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 9,510 | -2.86% | 281,711 |
| 24-04-25 | 9,790 | -1.90% | 240,735 |
| 24-04-24 | 9,980 | +0.71% | 450,656 |
| 24-04-23 | 9,910 | -4.25% | 737,636 |
| 24-04-22 | 10,350 | +12.38% | 1,091,686 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
MedPacto, Inc. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +31.35% | 232M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- A235980 Stock
